» Articles » PMID: 32034506

Cost-effectiveness of Social Oocyte Freezing in Germany: Estimates Based on a Markov Model

Overview
Date 2020 Feb 9
PMID 32034506
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Is oocyte freezing for non-medical reasons-the so-called "social freezing" (SF)-cost-effective compared to standard in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) in Germany today?

Methods: We developed a model based on three strategies for women planning to postpone pregnancy. In each strategy, women actively practiced contraception until 40 then tried to conceive naturally for 1 year. If unsuccessful, women using strategy I (oocyte cryopreservation) attempted ICSI with frozen oocytes in the 2nd year, while women using strategy II (no action) further attempted natural conception. In strategy III (IVF/ICSI), women underwent 1 year of IVF/ICSI. If still unsuccessful, each strategy was followed by attempting natural conception again until 45. We used an adaptive Markov model to estimate and compare live birth rates and cost-effectiveness measures.

Results: For strategy I, cumulative live birth rates at age 45 generally declined with the woman's age at freezing and were between 71.4% (25 years) and 67.6% (38 years), while the cumulative success rate was 51.5% for strategy II and 60.8% for strategy III. The costs per live birth of egg freezing were age-dependent ranging between 22,418 € (30 years) and 25,590 € (38 years). The costs for strategy III were lower at 20,293 € per live birth.

Conclusion: Based on our results, social freezing in Germany may lead to additional pregnancies among women over 40 but also to significantly higher costs, since given the current live birth success rates and pricing, social freezing does not appear to be cost-effective.

Citing Articles

Systematic review of the economic evaluation model of assisted reproductive technology.

Si Y, Tan T, Pu K Health Econ Rev. 2024; 14(1):34.

PMID: 38767759 PMC: 11103951. DOI: 10.1186/s13561-024-00509-3.


Main topics in assisted reproductive market: A scoping review.

Aderaldo J, Rodrigues de Albuquerque B, Camara de Oliveira M, de Medeiros Garcia Torres M, Lanza D PLoS One. 2023; 18(8):e0284099.

PMID: 37527215 PMC: 10393141. DOI: 10.1371/journal.pone.0284099.


Which assisted reproductive technology (ART) treatment strategy is the most clinically and cost-effective for women of advanced maternal age: a Markov model.

Lee E, Zhang J BMC Health Serv Res. 2022; 22(1):1197.

PMID: 36151546 PMC: 9508737. DOI: 10.1186/s12913-022-08485-2.


Usage and cost-effectiveness of elective oocyte freezing: a retrospective observational study.

Yang I, Wu M, Chao K, Wei S, Tsai Y, Huang T Reprod Biol Endocrinol. 2022; 20(1):123.

PMID: 35974356 PMC: 9380307. DOI: 10.1186/s12958-022-00996-1.


Elective oocyte cryopreservation for age-related fertility decline.

Chronopoulou E, Raperport C, Sfakianakis A, Srivastava G, Homburg R J Assist Reprod Genet. 2021; 38(5):1177-1186.

PMID: 33608838 PMC: 7894970. DOI: 10.1007/s10815-021-02072-w.